Top Insights
Health
globalreutersNovember 14, 20241 Mins read
PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain
globalreutersNovember 14, 20241 Mins read 
The PTC Therapeutics gene therapy, Kebilidi, treats an enzyme deficiency that affects the body’s ability to produce dopamine, a neurotransmitter important for motor control. FDA approval for the product comes two years after it won its first regulatory approvals in Europe.
The post PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain appeared first on MedCity News.
Leave a comment